Practice Note: How Bio-Rad’s old FCPA settlement became a ‘risk factor’

You would expect investors to be pleased and optimistic when their company resolves an FCPA case by paying relatively moderate penalties and landing a DOJ non-prosecution agreement, but one company thinks investors should also be concerned.